Characterisation of Ki11502 as a potent inhibitor of PDGF β receptor-mediated proteoglycan synthesis in vascular smooth muscle cells

European Journal of Pharmacology

Volumn 626, Issue 2-3, 2010, Pages 186-192

  Getachew, Robel ^a   Ballinger, Mandy L ^a   Burch, Micah L ^a,b   Little, Peter J ^a,b   Osman, Narin ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Biglycan; Ki11502; Platelet derived growth factor; Proteoglycan; Vascular smooth muscle cell; Xyloside

Indexed keywords

ADENOSINE; GLYCOSAMINOGLYCAN; GUANOSINE; KI 11502; N [4 [(6,7 DIMETHOXY 4 QUINOYL)OXY]PHENYL] N' [2 METHYLBENZOYL]THIOUREA; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEOGLYCAN; SULFATE; SULFUR 35; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CHROMATOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

DNA; GLYCOSAMINOGLYCANS; GLYCOSIDES; HUMANS; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PROTEOGLYCANS; QUINOLINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 70749142332     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.09.066     Document Type: Article

References (41)

1. Ballinger M.L., Nigro J., Frontanilla K.V., Dart A.M., and Little P.J. Regulation of glycosaminoglycan structure and atherogenesis. Cell. Mol. Life Sci. 61 (2004) 1296-1306
2. Ballinger M.L., Osman N., Wilks A.F., Su S., Burns C.J., Bu X., and Little P.J. Pyrido-pyrimidine derivative CYC10424 inhibits glycosaminoglycan changes on vascular smooth muscle-derived proteoglycans and reduces lipoprotein binding. J. Cardiovasc. Pharmacol. 52 (2008) 403-412
3. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
4. Chamley-Campbell J., Campbell G.R., and Ross R. The smooth muscle cell in culture. Physiol. Rev. 59 (1979) 1-61
5. Fritz T.A., and Esko J.D. Xyloside priming of glycosaminoglycan biosynthesis and inhibition of proteoglycan assembly. In: Iozzo R.V. (Ed). Proteoglycan Protocols (2001), Humana Press Inc, Totowa, NJ 317-324
6. Furuta T., Sakai T., Senga T., Osawa T., Kubo K., Shimizu T., Suzuki R., Yoshino T., Endo M., and Miwa A. Identification of potent and selective inhibitors of PDGF receptor autophosphorylation. J. Med. Chem. 49 (2006) 2186-2192
7. Heldin C.H. Development and possible clinical use of antagonists for PDGF and TGF-beta. Ups. J. Med. Sci. 109 (2004) 165-178
8. Heldin C.H., and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79 (1999) 1283-1316
9. Huang C.Y., Hao L.Y., and Buetow D.E. Hypertrophy of cultured adult rat ventricular cardiomyocytes induced by antibodies against the insulin-like growth factor (IGF)-I or the IGF-I receptor is IGF-II-dependent. Mol. Cell. Biochem. 233 (2002) 65-72
10. Kamimura M., Bea F., Akizawa T., Katus H.A., Kreuzer J., and Viedt C. Platelet-derived growth factor induces tissue factor expression in vascular smooth muscle cells via activation of Egr-1. Hypertension 44 (2004) 944-951
11. Kornowski R., Mintz G.S., Kent K.M., Pichard A.D., Satler F., Bucher T.A., Hong M.K., Popma J.J., and Leon M.B. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. Circulation 95 (1997) 1366-1369
12. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267 (1995) 1782-1788
13. Little P.J., Allen T.J., Hashimura K., Nigro J., Farrelly C.A., and Dilley R.J. High glucose potentiates mitogenic responses of cultured ovine coronary smooth muscle cells to platelet derived growth factor and transforming growth factor-beta1. Diabetes Res. Clin. Pract. 59 (2003) 93-101
14. Little P.J., Ballinger M.L., and Osman N. Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. Vas. Health Risk Manag. 3 (2007) 1-8
15. Little P.J., Cohen N., and Morahan G. Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes. Sci. World J. 9 (2009) 224-228
16. Little P.J., Osman N., and O'Brien K.D. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr. Opin. Lipidol. 19 (2008) 448-454
17. Little P.J., Tannock L., Olin K.L., Chait A., and Wight T.N. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 55-60
18. Louvet C., Szot G.L., Lang J., Lee M.R., Martinier N., Bollag G., Zhu S., Weiss A., and Bluestone J.A. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 18895-18900
19. Mundschau L.J., Forman L.W., Weng H., and Faller D.V. Platelet-derived growth factor (PDGF) induction of egr-1 is independent of PDGF receptor autophosphorylation on tyrosine. J. Biol. Chem. 269 (1994) 16137-16142
20. Myllarniemi M., Frosen J., Calderon Ramirez L.G., Buchdunger E., Lemstrom K., and Hayry P. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc. Drugs Ther. 13 (1999) 159-168
21. Nakashima Y., Fujii H., Sumiyoshi S., Wight T.N., and Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1159-1165
22. Nakashima Y., Wight T.N., and Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc. Res. 79 (2008) 14-23
23. Neylon C.B., Little P.J., Cragoe Jr. E.J., and Bobik A. Intracellular pH in human arterial smooth muscle. Regulation by Na+/H + exchange and a novel 5-(N-ethyl-N-isopropyl)amiloride-sensitive Na(+)- and HCO3(-)-dependent mechanism. Circ. Res. 67 (1990) 814-825
24. Nigro J., Ballinger M., Dilley R., Jennings G., Wight T., and Little P. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces LDL binding. Diabetologia 47 (2004) 2105-2113
25. Nigro J., Dilley R.J., and Little P.J. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 162 (2002) 119-129
26. Nishioka C., Ikezoe T., Yang J., Miwa A., Tasaka T., Kuwayama Y., Togitani K., Koeffler H.P., and Yokoyama A. Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood 111 (2008) 5086-5092
27. O'Brien E.R., Alpers C.E., Stewart D.K., Ferguson M., Tran N., Gordon D., Benditt E.P., Hinohara T., Simpson J.B., and Schwartz S.M. Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ. Res. 73 (1993) 223-231
28. Potter-Perigo S., Braun K.R., Schonherr E., and Wight T.N. Altered proteoglycan synthesis via the false acceptor pathway can be dissociated from beta-D-xyloside inhibition of proliferation. Arch. Biochem. Biophys. 297 (1992) 101-109
29. Ross R. Platelet-derived growth factor. Annu. Rev. Med. 38 (1987) 71-79
30. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
31. Ross R., G J.A., Kariya B., and Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc. Natl. Acad. Sci. U. S. A. 71 (1974) 1207-1210
32. Schonherr E., Jarvelainen H.T., Kinsella M.G., Sandell L.J., and Wight T.N. Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler. Thromb. 13 (1993) 1026-1036
33. Schonherr E., Jarvelainen H.T., Sandell L.J., and Wight T.N. Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J. Biol. Chem. 266 (1991) 17640-17647
34. Schonherr E., Kinsella M.G., and Wight T.N. Genistein selectively inhibits platelet-derived growth factor- stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch. Biochem. Biophys. 339 (1997) 353-361
35. Survase S., Ivey M.E., Nigro J., Osman N., and Little P.J. Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis. Vas. Health Risk Manag. 1 (2005) 199-208
36. Tabas I., Williams K.J., and Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116 (2007) 1832-1844
37. Takuma T., Tajima Y., and Ichida T. Effect of genistein on amylase release and protein tyrosine phosphorylation in parotid acinar cells. FEBS Lett. 380 (1996) 83-86
38. Tao Z., Smart F.W., Figueroa J.E., Glancy D.L., and Vijayagopal P. Elevated expression of proteoglycans in proliferating vascular smooth muscle cells. Atherosclerosis 135 (1997) 171-179
39. Wasteson A., Uthne K., and Westermark B. A novel assay for the biosynthesis of sulphated polysaccharide and its application to studies on the effects of somatomedin on cultured cells. Biochem. J. 136 (1973) 1069-1074
40. Wight T.N. Cell biology of arterial proteoglycans. Arteriosclerosis 9 (1989) 1-20
41. Yu J.Y., Lee J.J., Lim Y., Kim T.J., Jin Y.R., Sheen Y.Y., and Yun Y.P. Genistein inhibits rat aortic smooth muscle cell proliferation through the induction of p27kip1. J. Pharm. Sci. 107 (2008) 90-98